128 related articles for article (PubMed ID: 37114307)
21. Efficacy of transcatheter arterial chemoembolization combined with 125I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma.
Zhang H; Yang A; Zhang J
J BUON; 2020; 25(2):952-958. PubMed ID: 32521891
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.
He Q; Guo M; Ya Y; Huang J; Liu A; Jing W
Am J Transl Res; 2023; 15(5):3579-3585. PubMed ID: 37303659
[TBL] [Abstract][Full Text] [Related]
23. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
24. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
26. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation.
Lin JJ; Jin CN; Zheng ML; Ouyang XN; Zeng JX; Dai XH
Chin J Integr Med; 2005 Jun; 11(2):104-10. PubMed ID: 16150196
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
29. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
30. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma.
Zhou Z; Qin H; Weng L; Ni Y
J BUON; 2019; 24(2):615-621. PubMed ID: 31128014
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.
Luo J; Gao B; Lin Z; Fan H; Ma W; Yu D; Yang Q; Tian J; Yang X; Li B
Front Oncol; 2022; 12():1010726. PubMed ID: 36620586
[TBL] [Abstract][Full Text] [Related]
33. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
Fan W; Zhu B; Yue S; Zheng X; Zou X; Li F; Qiao L; Wu Y; Xue M; Wang H; Tang Y; Li J
Cancer Med; 2023 Jan; 12(1):61-72. PubMed ID: 35698292
[TBL] [Abstract][Full Text] [Related]
34. Observation of efficacy of TACE combined with HIFU on patients with middle-advanced liver cancer.
Zhang Q; Bian SQ; Lv W; Kou D; Hu HL; Guo SS; Cao ZS
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):239-246. PubMed ID: 31389607
[TBL] [Abstract][Full Text] [Related]
35. The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
Kawamura A; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Take A; Sakaguchi Y; Numata K; Kako M; Nozaki A; Azuma S; Horio K; Kusano C; Atsuda K
BMC Cancer; 2022 Aug; 22(1):912. PubMed ID: 35999529
[TBL] [Abstract][Full Text] [Related]
36. The effects of interventional therapy on serum HTATIP2/TIP30, B7-H4 and short-term curative effect in primary hepatocellular carcinoma.
Zheng ZJ; Fu J; Zhi F; Liu WJ; Guo YJ; Zhu DD; Mo JG
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6778-6783. PubMed ID: 30402840
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Hu L; Zheng Y; Lin J; Shi X; Wang A
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102061. PubMed ID: 36473632
[TBL] [Abstract][Full Text] [Related]
39. [The value of serum glypican-3 level in aided diagnosis of patients with primary hepatocellular carcinoma].
Tang XY; Wang YC; Lu RQ; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):998-1002. PubMed ID: 32907292
[No Abstract] [Full Text] [Related]
40. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
Chen K; Wei W; Liu L; Deng ZJ; Li L; Liang XM; Guo PP; Qi LN; Zhang ZM; Gong WF; Huang S; Yuan WP; Ma L; Xiang BD; Li LQ; Zhong JH
Cancer Immunol Immunother; 2022 May; 71(5):1063-1074. PubMed ID: 34559308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
